Arcturus Therapeutics Has Begun A Phase 1/2 Study On Its Covid-19 Vaccine Candidate

Arcturus Therapeutics announced this morning that it has initiated dosing of its Covid-19 vaccine candidate--LUNAR COV-19, (ARCT-021)--in a Phase 1/2 study in collaboration with Duke-NUS hospital in Singapore.